A Randomized, Single Center, Comparative Study to Evaluate the Efficacy and Safety of Silibinin (Legalon SIL) in Combination With Ribavirin or With Peginterferon and Ribavirin, Versus Peginterferon and Ribavirin Based Standard of Care (SoC) in Treatment of naive Genotype 4 Patients With Chronic Hepatitis C

Trial Profile

A Randomized, Single Center, Comparative Study to Evaluate the Efficacy and Safety of Silibinin (Legalon SIL) in Combination With Ribavirin or With Peginterferon and Ribavirin, Versus Peginterferon and Ribavirin Based Standard of Care (SoC) in Treatment of naive Genotype 4 Patients With Chronic Hepatitis C

Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 11 Mar 2015

At a glance

  • Drugs Silibinin (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms HEPASIL
  • Sponsors Rottapharm Madaus
  • Most Recent Events

    • 04 Mar 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 17 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top